Cargando…
Sotrovimab in SARS-COV-2 chronic hemodialysis patients in the Omicron era. Is intradialytic administration feasible? Report of 4 cases
Chronic hemodialysis patients are at high risk of morbidity and mortality in case of SARS-CoV-2 infection and they may need to be treated with monoclonal antibodies, either because they have not been vaccinated, or because they have a low anti spike antibody titer. Administration of Sotrovimab has r...
Autores principales: | Mambelli, Emanuele, Gasperoni, Lorenzo, Maldini, Laura, Biagetti, Carlo, Rigotti, Angelo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469048/ https://www.ncbi.nlm.nih.gov/pubmed/36098880 http://dx.doi.org/10.1007/s40620-022-01449-z |
Ejemplares similares
-
Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
por: Focosi, Daniele, et al.
Publicado: (2022) -
Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022) -
Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022) -
Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022) -
LB1577. Outcomes of Pregnant Women Exposed to Sotrovimab for the Treatment of COVID-19 in the Omicron Predominant Era (PRESTO)
por: Tuan, Jessica, et al.
Publicado: (2022)